Ascendis Health Past Earnings Performance

Past criteria checks 0/6

Ascendis Health has been growing earnings at an average annual rate of 22.7%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been declining at an average rate of 33.8% per year.

Key information

22.7%

Earnings growth rate

23.7%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate-33.8%
Return on equity-7.9%
Net Margin-3.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

There Is A Reason Ascendis Health Limited's (JSE:ASC) Price Is Undemanding

Sep 23
There Is A Reason Ascendis Health Limited's (JSE:ASC) Price Is Undemanding

Revenue & Expenses Breakdown

How Ascendis Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

JSE:ASC Revenue, expenses and earnings (ZAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,496-516290
30 Sep 231,516-1686320
30 Jun 231,535-2866350
31 Mar 231,547-2776240
31 Dec 221,559-2685600
30 Sep 221,559-5135920
30 Jun 221,559-7596240
31 Mar 221,833-1,2117400
31 Dec 212,107-1,6638560
30 Sep 211,966-1,6777980
30 Jun 211,825-1,6917410
31 Mar 21761-1,9853520
31 Dec 20-304-2,280-360
30 Sep 20949-1,8963470
30 Jun 202,203-1,5127300
31 Mar 205,761-1,3721,7120
31 Dec 195,417-1,8841,6850
30 Sep 195,644-1,8361,7130
30 Jun 195,872-1,7881,7400
31 Mar 195,494-9121,7320
31 Dec 185,116-361,7240
30 Sep 185,313-11,7210
30 Jun 185,511341,7170
31 Dec 177,1524061,7800
30 Sep 176,7803731,6940
30 Jun 176,4093401,6090
31 Dec 165,1542041,3430
30 Sep 164,5341811,1870
30 Jun 163,9141591,0300
31 Mar 163,6362049550
31 Dec 153,3542539020
30 Sep 153,0852318480
30 Jun 152,8172107940
31 Dec 142,2891717370
30 Sep 141,9541546430
30 Jun 141,6181365500
31 Dec 13950683030
30 Sep 13774392510

Quality Earnings: ASC is currently unprofitable.

Growing Profit Margin: ASC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ASC is unprofitable, but has reduced losses over the past 5 years at a rate of 22.7% per year.

Accelerating Growth: Unable to compare ASC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.9%).


Return on Equity

High ROE: ASC has a negative Return on Equity (-7.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.